| scholarly article | Q13442814 |
| P2093 | author name string | Suresh S Ramalingam | |
| Ticiana A Leal | |||
| P2860 | cites work | Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade | Q24535835 |
| Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer | Q24633070 | ||
| Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation | Q24675931 | ||
| Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial | Q27853359 | ||
| PD-L2 is a second ligand for PD-1 and inhibits T cell activation | Q28202471 | ||
| Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer | Q29615679 | ||
| Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients | Q29617771 | ||
| Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates | Q29620051 | ||
| Pembrolizumab for the treatment of non-small-cell lung cancer | Q29620851 | ||
| Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer | Q29620902 | ||
| Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer | Q29620913 | ||
| Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. | Q30275719 | ||
| Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival. | Q30847275 | ||
| PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions | Q33753894 | ||
| In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates | Q34421845 | ||
| Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy | Q34547495 | ||
| Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity | Q35870655 | ||
| Treatment Paradigms for Patients with Metastatic Non-Small-Cell Lung Cancer: First-, Second-, and Third-Line | Q36040619 | ||
| Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer | Q36352827 | ||
| Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). | Q36400381 | ||
| Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial | Q38364028 | ||
| Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer | Q38975751 | ||
| Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors | Q39089944 | ||
| PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project | Q39135152 | ||
| Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial | Q39704999 | ||
| Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial | Q40163779 | ||
| Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. | Q40236161 | ||
| Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. | Q40408396 | ||
| EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. | Q41112103 | ||
| Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy | Q41983246 | ||
| Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. | Q44204596 | ||
| P2.39: Long-Term OS for Patients With Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab: Track: Immunotherapy | Q46888796 | ||
| Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer | Q47834638 | ||
| Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody | Q53518554 | ||
| Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy | Q53521886 | ||
| Checkpoint Inhibitors: Common Immune-Related Adverse Events and Their Management | Q95505792 | ||
| P433 | issue | Suppl 3 | |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | S422-S432 | |
| P577 | publication date | 2018-02-01 | |
| P1433 | published in | Journal of thoracic disease | Q26841814 |
| P1476 | title | Immunotherapy in previously treated non-small cell lung cancer (NSCLC). | |
| P478 | volume | 10 |
Search more.